{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:25Z","timestamp":1792839865842,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are autoimmune central nervous system disorders with poorly understood immune pathways. CD83 plays a crucial role in the development and maintenance of immune tolerance. This study aims to evaluate CD83 expression in NMOSD and MOGAD and its correlation with disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RNA extracted from PBMCs of MOGAD, NMOSD and healthy controls (HCs) was analyzed to assess CD83 expression levels. ELISA was used to quantify soluble CD83 (sCD83) levels in the CSF and serum of patients. Additionally, the effects of therapeutic agents used for CNS demyelinating diseases on sCD83 expression levels were examined. The study enrolled 231 untreated participants, including 64 with MOGAD, 56 with NMOSD, 47 with MS, and 64 HCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NMOSD patients exhibited lower sCD83 levels compared to MOGAD and HCs, and MOGAD patients with a relapsing course had lower sCD83 levels than those with a monophasic course. Lower sCD83 levels correlated with a severe disease course. Treatment with IVIG and azathioprine significantly increased sCD83 levels in the patients\u2019 serum. <jats:italic>In vitro<\/jats:italic> treatment with immunosuppressives led to a significant increase in sCD83 levels with the most pronounced effect observed following treatment with mycophenolate mofetil.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study consistently found lower sCD83 levels in NMOSD and relapsing MOGAD patients. sCD83 levels increased following IVIG and immunosuppressive therapy. This elevation may reflect either a direct effect of the therapy itself, or a compensatory rebound response following immune suppression. These findings highlight the potential of sCD83 as a prognostic biomarker in these diseases and support its role as both a therapeutic target and a marker for treatment response in CNS demyelinating disorders.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1620069","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:46Z","timestamp":1753330246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway"],"prefix":"10.3389","volume":"16","author":[{"given":"Ariel","family":"Rechtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Zveik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyne","family":"Shweiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrick","family":"Hoichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Friedman-Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livnat","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1209749","article-title":"Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders","volume":"14","author":"Takai","year":"2023","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2016.1150178","article-title":"Therapeutic options in neuromyelitis optica spectrum disorders","volume":"16","author":"Kitley","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicenter, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.783304","article-title":"Can immune tolerance be re-established in neuromyelitis optica","volume":"12","author":"Loda","year":"2021","journal-title":"Front Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/BF02934736","article-title":"Immunological tolerance and autoimmunity","volume":"1","author":"Romagnani","year":"2006","journal-title":"Intern Emerg Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.2511629","article-title":"A nondeletional mechanism of thymic self tolerance","volume":"246","author":"Ramsdell","year":"1989","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744804","article-title":"Approaches to establishing tolerance in immune mediated diseases","volume":"12","author":"Huffaker","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07079-8","article-title":"B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4","volume":"627","author":"Afzali","year":"2024","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favor anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01312","article-title":"CD83: activation marker for antigen presenting cells and its therapeutic potential","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1038\/s41467-023-40370-2","article-title":"Microglial expression of CD83 governs cellular activation and restrains neuroinflammation in experimental autoimmune encephalomyelitis","volume":"14","author":"Sinner","year":"2023","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.6672","article-title":"Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation","volume":"174","author":"Dudziak","year":"2005","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00721","article-title":"The CD83 molecule \u2013 an important immune checkpoint","volume":"11","author":"Grosche","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00633","article-title":"Soluble CD83 triggers resolution of arthritis and sustained inflammation control in IDO dependent manner","volume":"10","author":"Royzman","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201531","article-title":"Topical application of soluble CD83 induces IDO-mediated immune modulation, increases foxp3+ T cells, and prolongs allogeneic corneal graft survival","volume":"191","author":"Bock","year":"2013","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13654","article-title":"CD83\n            + B cells alleviate uveitis through inhibiting DCs by sCD83","volume":"170","author":"Feng","year":"2023","journal-title":"Immunology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99712","article-title":"CD83 expression is essential for Treg cell differentiation and stability","volume":"3","author":"Doebbeler","year":"2018","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126246","article-title":"CD83 orchestrates immunity toward self and non-self in dendritic cells","volume":"4","author":"Wild","year":"2019","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.79","article-title":"Dendritic cell CD83 homotypic interactions regulate inflammation and promote mucosal homeostasis","volume":"8","author":"Bates","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030973","article-title":"Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83","volume":"200","author":"Zinser","year":"2004","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.38722","article-title":"Soluble CD83 alleviates experimental allergic rhinitis through modulating antigen-specific Th2 cell property","volume":"16","author":"Wu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01567","article-title":"Soluble CD83 alleviates experimental autoimmune uveitis by inhibiting filamentous actin-dependent calcium release in dendritic cells","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pneurobio.2016.05.001","article-title":"Functions and mechanisms of microglia\/macrophages in neuroinflammation and neurogenesis after stroke","volume":"142","author":"Xiong","year":"2016","journal-title":"Prog Neurobiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","article-title":"Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer\u2019s disease","volume":"11","author":"Olah","year":"2020","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1038\/s41467-024-49790-0","article-title":"Single cell transcriptomes and multiscale networks from persons with and without Alzheimer\u2019s disease","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.17.540842","article-title":"RNA- and ATAC-sequencing reveals a unique CD83+ Microglial population focally depleted in parkinson\u2019s disease","author":"Chatila","year":"2023"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1293828","article-title":"Soluble CD83 modulates human-monocyte-derived macrophages toward alternative phenotype, function, and metabolism","volume":"14","author":"Peckert-Maier","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00673-6","article-title":"CD83 expression influences CD4+ T cell development in the thymus","volume":"108","author":"Fujimoto","year":"2002","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12438-6","article-title":"Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings","volume":"271","author":"Rechtman","year":"2024","journal-title":"J Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.867190","article-title":"Volumetric brain loss correlates with a relapsing MOGAD disease course","volume":"13","author":"Rechtman","year":"2022","journal-title":"Front. Neurol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.07.037","article-title":"Temporal aspects of visual perception in demyelinative diseases","volume":"357","author":"Raz","year":"2015","journal-title":"J Neurol Sci"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-19515-1_5","article-title":"Immune tolerance in autoimmune central nervous system disorders","volume-title":"Neuroimmune Diseases.","author":"Jayaraman","year":"2019"},{"key":"B45","doi-asserted-by":"publisher","first-page":"578351","DOI":"10.1016\/j.jneuroim.2024.578351","article-title":"A protective effect of lower MHC-II expression in MOGAD","volume":"391","author":"Rechtman","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr\u00a0Opin Neurol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1011579","article-title":"Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD","volume":"13","author":"Fadda","year":"2022","journal-title":"Front Neurol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol - Neuroimmunol Neuroinflamm"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.04.005","article-title":"The levels of soluble forms of CD21 and CD83 in multiple sclerosis","volume":"320","author":"Karampoor","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann Neurol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1085742","article-title":"CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation","volume":"14","author":"Peckert-Maier","year":"2023","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/0891693031000089427","article-title":"Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission","volume":"36","author":"Hollifield","year":"2003","journal-title":"Autoimmunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1037812","article-title":"Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"13","author":"Bauer","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2015.11.006","article-title":"Immunosuppressive drugs affect induction of IFNy+ Treg","volume":"77","author":"Daniel","year":"2016","journal-title":"vitro. Hum Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1097\/01.TP.0000067950.90241.1D","article-title":"Effects of immunosuppressive drugs on dendritic cells and tolerance induction","volume":"75","author":"Lagaraine","year":"2003","journal-title":"Transplantation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2009.11.001","article-title":"Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA\/6-MP","volume":"218","author":"Aldinucci","year":"2010","journal-title":"J Neuroimmunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","article-title":"Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells","volume":"133","author":"Massoud","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13075-020-02356-z","article-title":"Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells","volume":"22","author":"Shigesaka","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1212\/NXI.0000000000000066","article-title":"Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder","volume":"2","author":"Kornberg","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000430","article-title":"Severe relapses of neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate","volume":"44","author":"Javadian","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577790","article-title":"Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","volume":"363","author":"Ma","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(03)00035-1","article-title":"Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases","volume":"10","author":"Bayry","year":"2003","journal-title":"Transfus Clin Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:47Z","timestamp":1753330247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1620069"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620069","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1620069"}}